The platelet-endothelium interaction mediated by lectin-like oxidized low-density lipoprotein receptor-1 reduces the intracellular concentration of nitric oxide in endothelial cells  by Cominacini, Luciano et al.
EXPERIMENTAL STUDIES
The Platelet-Endothelium Interaction
Mediated by Lectin-Like Oxidized Low-Density
Lipoprotein Receptor-1 Reduces the Intracellular
Concentration of Nitric Oxide in Endothelial Cells
Luciano Cominacini, MD,* Anna Fratta Pasini, MD,* Ulisse Garbin, MD,* Antonio Pastorino, BSC,*
Anna Rigoni, MD,* Cristina Nava, MD,* Anna Davoli, BSC,* Vincenzo Lo Cascio, MD,*
Tatsuya Sawamura, MD†
Verona, Italy; and Osaka, Japan
OBJECTIVES To address the potential role of the endothelial lectin-like oxidized low-density lipoprotein
receptor-1 (LOX-1) in the thrombotic system, in this study we first examined whether
platelet interaction with LOX-1 generated reactive oxygen species (ROS) and superoxide
(O2
 ) and then investigated the relationship between the intracellular production of O2
 and
the availability of nitric oxide (NO).
BACKGROUND Oxidative inactivation of NO is regarded as an important cause of its decreased biologic
activity which may favor platelet-dependent arterial thrombosis.
METHODS Bovine aortic endothelial cells (BAECs) and Chinese hamster ovary-K1 cells stably
expressing bovine LOX-1 (BLOX-1-CHO) were incubated at different times with human
platelets. The ROS, O2
 , and NO were measured in cells by flow cytometry.
RESULTS The incubation of BAECs and BLOX-1-CHO cells with human platelets induced a sharp
and dose-dependent increase in intracellular concentration of ROS and O2
 (p from 0.01
to 0.001). The increase in intracellular concentration of O2
 was followed by a dose-
dependent reduction in basal and bradykinin-induced intracellular NO concentration (p from
0.01 to 0.001). The increase in O2
 and the reduction of NO were inhibited by the
presence of vitamin C and anti-LOX-1 monoclonal antibody (p  0.001).
CONCLUSIONS The results of this study show that one of the pathophysiologic consequences of platelet binding
to LOX-1 may be the inactivation of NO through an increased cellular production of O2
 . (J Am
Coll Cardiol 2003;41:499–507) © 2003 by the American College of Cardiology Foundation
BASIC SCIENCE IN CONTEXT
Focus on the endothelial cell response to activated platelets. Endothelial
dysfunction is important in the pathogenesis of atherosclerosis and acute
coronary syndromes. Multiple risk factors contribute to endothelial injury,
such as dyslipidemia, platelet activation, oxidant stress, inflammation,
hypertension, and diabetes. Although therapy aimed at activating factors is
effective (e.g., platelet inhibition for the treatment and prevention of acute
coronary syndromes), complementary approaches are needed to protect the
target cell and prevent endothelial cell dysfunction. This study examines a
novel mechanism for platelet-vascular endothelial interactions to induce
endothelial cell damage.
Oxidized low-density lipoprotein (ox-LDL) damages endothelial cells and
impairs the release of nitric oxide (NO), a key regulator of normal
endothelial function. Oxidized low-density lipoprotein binds to endothelial
cells by scavenger receptors, including lectin-like ox-LDL receptor-1
(LOX-1), a recently described receptor for ox-LDL. This study demonstrates
that activated human platelets also target LOX-1. Similar to ox-LDL,
activated platelets induce a LOX-1–mediated increase in reactive oxygen
species and superoxide that decrease NO availability in endothelial cells.
This dual role makes LOX-1 a novel therapeutic target for preventing
endothelial dysfunction induced by ox-LDL or by activated platelets.
—Wilbur Y. W. Lew
University of California at San Diego
VA San Diego Healthcare System
La Jolla, California
Nitric oxide was originally discovered as a vasodilator
product of the endothelium (1–3). It is known that there is
decreased NO availability in the early stages of atheroscle-
rosis (4) and in the presence of vascular risk factors (5)
which contribute to the impairment of endothelium-
dependent relaxation (6,7). Nitric oxide possesses many
anti-atherogenic properties (8–11). Oxidative inactivation
of NO is regarded as an important cause of its decreased
biologic activity (12). In this context, it has recently been
shown that the binding of ox-LDL to an endothelial
scavenger receptor called LOX-1 activates the transcription
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factor, nuclear factor kappa-B, through an increased pro-
duction of reactive oxygen species (ROS) (13) and super-
oxide (O2
 ) (14). The LOX-1 is highly expressed in vascular
endothelial cells also in humans (15), and many pathologic
changes—including monocytes adhesion via up-regulation
of monocyte chemotactic protein-1 expression (16), and
induction of apoptosis (17)—have been reported to be
correlated to the activation of this receptor.
Very recently it has been demonstrated that LOX-1 is
also involved in the platelet-endothelium interaction
through its binding to phosphatidylserine (PS) and other
negatively charged phospholipids (18,19) that are mainly
exposed on the surface of platelets on activation (20).
Notably, the binding of platelets to LOX-1 enhanced
the release of endothelin-1 from endothelial cells, sup-
porting the induction of endothelial dysfunction, which
would in turn promote the atherogenic process (18).
To address the potential role of LOX-1 in the thrombotic
system, in this study we first examined whether platelet
interaction with endothelial cells generated ROS and O2
 in
endothelial cells. Then we investigated the relationship
between the intracellular production of ROS, and in par-
ticular of O2
 , and the intracellular concentration of NO in
endothelial cells exposed to platelets.
METHODS
Platelet preparation. Platelets were isolated by using the
standard method of Baenziger and Majerus (21). Blood
samples were obtained from healthy graduate student do-
nors who were medication-free and non-smokers (with
informed consent).
Cell cultures. Bovine aortic endothelial cells (BAECs)
were isolated and cultured as previously described (22).
Chinese hamster ovary-K1 (CHO-K1) cells stably express-
ing bovine LOX-1 (BLOX-1-CHO) were obtained by
transfecting a bovine LOX-1 expression vector, designated
pBLOX-1 (1 g), into CHO-K1 cells by the calcium
phosphate transfection method as described (15). The
CHO-K1 cells and BLOX-1-CHO cells were cultured as
previously described (22). Cell survival was monitored
according to the method of Landegren (23).
ROS and O2
 measurement. Intracellular ROS and O2

levels were measured as described (13,14) by following the
oxidation of 2,7-dichlorofluorescin diacetate (DCFH-
DA) and hydroethidine (HE) by flow cytometry (Coulter
Corporation, Hialeah, Florida). The BAECs were incu-
bated in Dulbecco’s modified Eagle medium (Sigma, St.
Louis, Missouri) containing 10% fetal bovine serum and
10 mol/l DCFH-DA or 1mol/l HE for 20 min. The
density of washed platelets was first adjusted to 1  108/ml
in Hepes-Tyrode’s buffer. Then different amounts of non-
activated and activated platelets (ranging from 1.5 107/ml
to 4.5 107/ml) were added to the BAEC medium for 5 to
30 min at 37°C in the presence of 5 mmol/l arginine and
3 mol/l tetrahydrobiopterin to prevent O2
 formation by
endothelial nitric oxide synthase (eNOS) (24). Platelets
were stimulated with different amounts of thrombin
(Sigma) (from 0.03 to 1 U/ml) (activated platelets). After 15
min, hirudin (Calbiochem, San Diego, California) was
added to a final concentration of 1 U/ml to inactivate
thrombin. To exclude any direct effect of thrombin and
hirudin on ROS and O2
 generated by the cells, thrombin
(1 U/ml) and hirudin (1 U/ml) were also added to the
control (BAECs without addition of platelets). Finally, to
exclude the interference of biologically highly active com-
pounds secreted by platelets on ROS and O2
 in BAECs,
the effects of platelet releasate (obtained by removing the
supernatant after centrifugating 4.5  107/ml thrombin-
activated platelets), and of some antagonists (preincubated
for 30 min before the addition of 4.5  107/ml thrombin-
activated platelets) such as SQ29548 (1 mol/l), a throm-
boxane A2 receptor antagonist (Cayman, Ann Arbor,
Michigan), ketanserin (5 mol/l), a serotonin receptor
antagonist (Alexis, San Diego, California), and yohimbine
(140 nmol/l), an alpha2-receptor antagonist (Sigma) were
evaluated. The adenosine diphosphate (ADP) scavengers
apyrase (Sigma) (1 U/ml) and phosphoenolpyruvate (PEP)-
pyruvate kinase (PK) (Alexis) (PEP  0.28 mmol/l, PK 
3 U/ml) were also preincubated for 5 min before the
addition of thrombin-activated platelets (4.5  107/ml).
To test the response specificity, vitamin C (5 mol/l) and
LOX-1 antibody (Ab) (30 g/ml) (15) were incubated with
BAECs, CHO-K1, and BLOX-1-CHO cells under the
experimental conditions specified previously. To compare
with other antibodies or antagonists possibly involved in
platelet–endothelium interaction, anti-CD41a (Pharmin-
gen, San Diego, California), anti-CD40L (Pharmingen),
anti-CD11a (Pharmingen), anti-CD62 (Santa Cruz, Santa
Cruz, California), anti-CD31 (Santa Cruz), and anti-von
Willebrand factor (Santa Cruz) antibodies, sialyl Lewis X
oligosaccharide (Calbiochem), and annexin V (Pharmingen)
were also preincubated with the medium.
Abbreviations and Acronyms
BAECs  bovine aortic endothelial cells
BLOX-1-CHO cells  CHO-K1 cells stably expressing
bovine LOX-1
CHO-K1 cells  Chinese hamster ovary-K1 cells
DAF-2 DA  4, 5 diaminofluorescein diacetate
DCFH-DA  2,7-dichlorofluorescin diacetate
eNOS  endothelial nitric oxide synthase
HE  hydroethidine
LOX-1  lectin-like ox-LDL receptor-1
LOX-1 Ab  anti-LOX-1 monoclonal
antibody
MFI  mean fluorescence intensity
NO  nitric oxide
O2
  superoxide
ox-LDL  oxidized low-density lipoprotein
PEP  phosphoenolpyruvate
PK  pyruvate kinase
PS  phosphatidylserine
ROS  reactive oxygen species
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The effect of PS (incubated as liposomes) on O2
 gener-
ation by BAECs, CHO-K1, and BLOX-1-CHO cells was
also evaluated. The PS liposomes were obtained as previ-
ously described (25). To determine which oxidative systems
contribute to the release of O2
 after platelet exposure,
BAECs were also preincubated with L- and D-N-
monomethyl arginine (L- and D-NMMA) (1 mmol/l), L-
and D-N-arginine (L-and D-NAME) (1 mmol/l), aspirin
(100 mol/l), oxypurinol (200 mol/l), rotenone (1 mol/
l), and diphenyleneiodonium (DPI) (100 mol/l).
NO measurement. Intracellular NO was measured in the
presence and absence of endothelial activation with brady-
kinin (100 nmol/l) (Sigma), as previously described (14),
using the fluorescent indicator 4,5 diaminofluorescein diac-
etate (DAF-2 DA) in flow cytometry (Coulter Electronics
GmBH). Confluent BAECs were incubated in Krebs
Ringer Phosphate buffer containing 10 mol/l DAF-2 DA
for 10 min at 37°C and with 100 nmol/l bradykinin (Sigma)
in the presence of 5 mmol/l arginine and 3 mol/l tetrahy-
drobiopterin. The NO production was also monitored by
following levels of nitrite in the supernatant of stimulated
BAECs and activated platelets (4.5  107/ml) and there-
after in the supernatant of stimulated BAECs incubated
with activated platelets. Concentrations of nitrite were
determined by a fluorimetric assay (26).
Different amounts of non-activated and thrombin-
activated platelets (ranging from 1.5  107/ml to 4.5 
107/ml) were added to BAECs for 10 min. To exclude any
direct effect of thrombin and hirudin on NO generated by
the cells, thrombin (1 U/ml) and hirudin (1 U/ml) were also
added to the control (BAECs without addition of platelets).
Finally, to exclude the interference of biologically highly
active compounds secreted by platelets on NO in BAECs,
the effects of platelet releasate and of the same antagonists
and ADP scavengers specified previously were evaluated.
To ascertain whether the effect of platelets on intracellu-
lar NO concentration was dependent on O2
 production
and to test the response specificity, vitamin C and LOX-1
Ab (15) were also used under the experimental conditions
specified earlier.
eNOS activity measurement. The effect of platelets on
eNOS metabolism of 3H arginine to 3H citrulline was
determined as described previously (14,27).
Statistical analysis. Statistical analysis was performed by
one- or two-way analysis of variance (ANOVA) for re-
peated measures followed by post hoc Tukey test for
multiple comparisons using the “SYSTAT” program and
statistical software manual (SYSTAT Inc., Evanston, Illi-
nois) for Macintosh. Statistical significance was inferred at p
values 0.05.
RESULTS
In our experimental conditions, the incubation of BAECs
with increasing amounts of platelets for 10 min induced a
sharp and dose-dependent increase in intracellular concen-
tration of ROS and O2
 (p from 0.01 to 0.001) (Fig.
1A). We also performed some time-course experiments of
O2
 formation in BAECs incubated with platelets activated
with different amounts of thrombin. By two-way ANOVA
with repeated measures, there was a significant effect for the
thrombin concentrations (p  0.001) and for the times of
incubation (p  0.001), with a significant concentrations/
times interaction (p  0.001) on O2
 generation. As shown
in Figure 1B, from the evaluation of the time-course of O2

formation in BAECs using post-ANOVA Tukey test for
multiple comparisons, it was clear that the effect of platelets
was already present after 2 min of incubation even with
submaximal doses of thrombin.
To exclude the interference of biologically highly active
compounds secreted by thrombin-activated platelets on
ROS and O2
 generated by BAECs, the effects of
thrombin-activated platelet releasate and of specific antag-
onists were analyzed. The incubation of thrombin-activated
platelet releasate with BAECs did not significantly affect
intracellular concentration of ROS and O2
 . Similarly the
preincubation of BAECs with SQ29548, ketanserin, yo-
himbine, and with the ADP scavengers apyrase and
PEP-PK did not modify intracellular ROS and O2
 con-
centration induced by activated platelets in BAECs.
To test the response specificity and to verify if O2

increase was dependent on platelets binding to LOX-1,
vitamin C and LOX-1 Ab were incubated with BAECs,
CHO-K1, and BLOX-1-CHO cells. As shown in Figure 2,
the O2
 concentration was markedly reduced in BAECs and
BLOX-1-CHO cells preincubated with vitamin C (p 
0.001) and LOX-1 Ab (p  0.001), whereas control
CHO-K1 cells were not affected. Besides LOX-1 Ab,
anti-CD41a slightly inhibited the production of O2
 , and
the simultaneous application of anti-LOX-1 and anti-
CD41a showed an additive effect (p  0.001). Finally,
annexin V significantly reduced the production of O2

induced by thrombin-activated platelets (p  0.001) (Fig.
3). Annexin V also decreased the generation of O2
 induced
by non-stimulated platelets (3  107/ml) by 14  1.3%
(p  0.05).
The PS liposomes (at concentrations of 10 and 20 mol/l
total lipids/106 cells) determined a dose-dependent increase
in O2
 production in BAECs (mean fluorescence intensity
[MFI] from 0.3  0.029 to 1.5  0.13 and to 2.7  0.23,
p  0.001, n  10) and BLOX-1-CHO cells (MFI from
0.24  0.020 to 1.8  0.17 and to 3.1  0.29, p  0.001,
n 10). The PS liposomes produced no effect on CHO-K1
cells.
Anti-CD40L, antiCD11a, anti-CD62, anti-CD31, anti-
VWF, sialyl Lewis X oligosaccharide, and control immu-
noglobulin G (IgG) did not affect O2
 generation.
The incubation of BAECs with increasing amounts of
platelets for 10 min in the presence of DAF-2 DA dose-
dependently reduced basal and bradykinin-induced intracel-
lular NO concentration (p from 0.01 to 0.001) (Fig. 4).
Similarly, concentrations of nitrite in the supernatant of
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stimulated BAECs dropped from 635  25 pmol/well to
211  12 pmol/well (p  0.001, n  12) after the addition
of activated platelets (4.5  107/ml), the contribution of
activated platelets alone being 124  8 pmol/4.5  107
platelets.
The incubation of platelet releasate with BAECs did not
significantly affect basal and stimulated concentration of
intracellular NO and supernatant nitrite. Similarly, the
preincubation of BAECs with SQ29548, ketanserin,
yohimbine, and with the ADP scavengers apyrase and
Figure 1. (A) Effect of different amounts of non-activated (T) and thrombin-activated (T) platelets on intracellular concentration of reactive oxygen
species (ROS) and superoxide in bovine aortic endothelial cells (BAECs). The BAECs were preincubated with 2,7-dichlorofluorescein diacetate and
hydroethidine at 37°C for 20 min. Different amounts of (T) and (T) platelets (from 0 to 4.5  107/ml) were added to the BAEC medium for 10 min
at 37°C. Results are expressed as mean fluorescence intensity (MFI) and are the means  SD of experiments performed in triplicate on six separate
occasions. ¶p  0.01, *p  0.001 vs. no addition of platelets (Control). (B) Time-course of superoxide formation induced by platelets activated with
different amounts of thrombin in BAECs. The BAECs were preincubated with hydroethidine for 20 min. Platelets (3  107/ml) activated with different
doses of thrombin (from 0.03 to 1 U/l) were added to the BAEC medium for the indicated times at 37°C. The BAECs and platelets alone were used as
controls. Results are expressed as MFI and are the means  SD of experiments performed in triplicate on six separate occasions. By two-way analysis of
variance there was a significant effect for the thrombin concentrations (p  0.001) and for the times of incubation (p  0.001) with a significant
concentrations/times interaction (p  0.001) on superoxide generation. Post-analysis of variance Tukey test for multiple comparisons: ¶p  0.01, *p 
0.001 vs. time 0.
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PEP-PK did not interfere with the modifications of basal
and stimulated intracellular NO and supernatant nitrite
induced by activated platelets.
To test if the reduction of intracellular NO concentration
induced by platelets was dependent on O2
 generation, we
preincubated BAECs with vitamin C and LOX-1 Ab.
Figure 5 shows that the preincubation of BAECs with
vitamin C and LOX-1 Ab significantly counteracted the
effect of activated platelets on basal and stimulated genera-
tion of NO (p from 0.01 to 0.001).
The effect of platelets on endothelial cell eNOS activity
was examined by the 3H citrulline assay. Activated platelets
(4.5  107/ml) did not significantly modify the ability of
eNOS to metabolize L-arginine to L-citrulline (BAECs 
76.6  10.4 pmol citrulline/mg protein/min, BAECs 
platelets  72  9.9 pmol citrulline/mg protein/min, p 
NS).
As for the oxidative system involved, we found that
aspirin, L-NAME, L-NMMA, D-NAME, D-NMMA,
oxypurinol, and rotenone did not modify O2
 concentration
in endothelial cells after platelet incubation, whereas DPI
drastically reduced the intracellular amount of O2
 (MFI
from 8.20  0.88 to 0.34  0.04, p  0.001, n  10).
DISCUSSION
Lectin-like ox-LDL receptor-1 is a type II membrane
protein with a C-type lectin-like structure at the C terminus
(15). The expression of LOX-1 in endothelial cells in vitro
and in vivo is highly regulated (22). Besides ox-LDL,
LOX-1 binds aged/apoptotic cells (19) and platelets (18).
The binding of platelets to LOX-1 has recently been shown
to increase the release of endothelin from endothelial cells
supporting the induction of endothelial dysfunction (18).
In this study, we demonstrated for the first time that the
binding of platelets to LOX-1 reduces the intracellular
concentration of NO in cultured BAECs. This decrease was
associated with a contemporary fall of nitrite in the super-
natant, indicating that the reduction in intracellular NO
concentrations also reflects the extracellular NO concentra-
tion. Taken together, these results suggest a role of platelets
in the selective impairment of endothelium-derived relax-
ation which is characteristic of the early stages of athero-
sclerosis (6,7).
The rapid decrease in NO induced by platelets was
paralleled by a specular fast increase in ROS and O2

formation. The increased cellular production of ROS and
O2
 was prevented by preincubating BAECs with vitamin
C, an antioxidant known to work as a radical scavenger and
with LOX-1 Ab. Furthermore, the incubation of platelets
with BLOX-1 CHO cells determined a time- and dose-
dependent significant increase in ROS and O2
 formation,
which once again were abolished by vitamin C and LOX-1
Ab. As for the effect of LOX-1 Ab, our results agree with
those of Kakutani et al. (18), who demonstrated that the
Figure 2. Effect of vitamin C (Vit. C) and anti-LOX-1 monoclonal antibody (LOX-1 Ab) on platelet-induced variations of O2
 concentration in bovine
aortic endothelial cells (BAECs), Chinese hamster ovary-K1 (CHO) cells, and CHO-K1 cells stably expressing bovine LOX-1 (BLOX-1-CHO) cells.
Vitamin C (5 mol/l) and LOX-1 Ab (30 g/ml) were preincubated with BAECs, BLOX-1-CHO, and CHO cells at 37° for 30 min. Thrombin-activated
platelets (3 107/ml) were then added to the cell medium for 10 min at 37°C. Results are expressed as mean fluorescence intensity (MFI) and are the means
 SD of experiments performed in triplicate on six separate occasions. *p  0.001 vs. platelets alone.
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preincubation of BAECs or BLOX-1 CHO cells with
LOX-1 Ab greatly reduced the binding of platelets to
LOX-1. To compare with other molecules possibly involved
in platelet-endothelium interaction, antibodies or antago-
nists for these molecules were introduced into the medium.
Besides LOX-1 Ab, anti-CD41a inhibited the O2
 forma-
tion approximately 25%, indicating that glycoprotein IIb/
IIIa-mediated binding is also involved in the platelet–
endothelium interaction. The simultaneous addition of
LOX-1 Ab and anti-CD41 antibody showed an additive
effect on O2
 , indicating, as previously shown (18), that
LOX-1 and glycoprotein IIb/IIIa work independently on
platelet-endothelium interaction. Anti-CD40L, anti-
CD11a, anti-CD62, anti-CD31, anti-VWF, sialyl Lewis X
oligosaccharide, and control IgG did not affect the O2

production induced by platelets.
As for the mechanism of platelet-endothelium interac-
tion, the results we obtained with annexin V, a PS binding
protein (28), are consistent with the hypothesis that PS may
be one of the major determinants of platelet binding to
LOX-1. Phosphatidylserine in fact is an efficient ligand for
LOX-1 (19), and although PS binding sites have also been
demonstrated in non-activated platelets (20), they are
mainly exposed on the surface of activated platelets (19,20).
In addition, the results of this study show that PS dose-
dependently increased O2
 production both in BAECs and
BLOX-1-CHO cells. Even if these results should be
considered preliminary, another conclusion of this study is
that PS not only may be one of the major determinants of
platelet binding to LOX-1, but may also trigger a train of
events leading to O2
 generation.
Taken together, these data show that the incubation of
platelets with BAECs is associated with an increased
intracellular production of ROS and O2
 and that the
platelet ligation to LOX-1 plays a crucial role in intracellular
ROS and O2
 generation. The results of this study also
demonstrate that the decrease of intracellular NO concen-
tration was prevented by preincubating BAECs with vita-
min C and with LOX-1 Ab. The data support the conclu-
sion that the incubation of platelets with BAECs is
associated with a receptor-dependent, abnormally increased
intracellular production of ROS, and in particular of O2
 .
Figure 3. Effect of anti-LOX-1 monoclonal antibody (LOX-1 Ab), anti-CD41a antibody, annexin V, and immunoglobulin G (IgG) on platelet-induced
variations of superoxide concentration in bovine aortic endothelial cells (BAECs). The LOX-1 Ab (30 g/ml), anti-CD41a antibody (30 g/ml) alone and
mixed with LOX-1 Ab, annexin V (10 mol/l), and IgG (30 g/ml) were preincubated with BAECs for 30 min at 37°C. Thrombin-activated platelets
(3  107/ml) were added to the cell medium for 10 min at 37°C. Results are expressed as percent variations of mean fluorescence intensity (MFI) and are
the means  SD of experiments performed in triplicate on six separate occasions. *p  0.001 vs. platelets alone.
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The NO decrease therefore may be secondary to O2

formation, which is known to inactivate NO in a chemical
reaction during which the cytotoxic radical peroxynitrite is
formed (12). In our experimental conditions, platelets did
not significantly alter the ability of eNOS to metabolize
L-arginine to L-citrulline. Because the conversion of 3H
arginine into 3H citrulline, under apparent maximum ve-
locity conditions (14,27), is a measure of eNOS levels, the
results of this study show that the binding of platelets to
LOX-1 did not alter, at least quantitatively, the ability to
produce NO.
As for the oxidative system involved in ROS and O2

generation, the results of this study clearly show that only
DPI, a non-selective inhibitor of nicotinamide adenine
dinucleotide phosphate (NADPH) oxidase (29), reduced
O2
 generation in BAECs stimulated by platelets. Because
specific inhibitors of cyclooxygenase, eNOS, xanthine oxi-
dase, and mitochondrial nicotinamide adenine dinucleotide
dehydrogenase did not reduce O2
 generation in BAECs
stimulated by platelets, another conclusion of this study is
that the increase of O2
 release after platelet exposure may
be related to the increased activity of endothelial NADPH
oxidase.
The decrease in intracellular NO concentration as a result
of O2
 generation may also have implications in vivo. For
example, the impaired endothelium-dependent vasodilation
is associated with an augmented susceptibility of atheroscle-
rotic blood vessels to the development of vasospasm in vivo
(6), the inappropriate constriction leading to ischemic man-
ifestations (30). Increased oxidative stress within the vascu-
lar wall may facilitate platelet activation (31,32). The O2

produced by the ligation of activated platelets to LOX-1
may finally inactivate NO in a chemical reaction during
which peroxynitrite is formed. Furthermore, a deficiency of
NO has been shown to be associated with arterial throm-
bosis in animal models (33) and in individuals with acute
coronary syndromes (34). The decrease in NO availability
induced by the binding of platelets to LOX-1 may, there-
fore, in turn further increase platelet activation, induce
adhesion and aggregation, and finally favor platelet-
dependent arterial thrombosis.
In conclusion, the results of this study show that one of
the pathophysiologic consequences of platelets binding to
LOX-1 may be the inactivation of NO through an increased
cellular production of O2
 .
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Figure 4. Effect of different amounts of non-activated (T) and thrombin-activated (T) platelets on basal and bradykinin-stimulated intracellular
concentration of nitric oxide (NO) in bovine aortic endothelial cells (BAECs). The BAECs were preincubated with 10 mol/l 4, 5 diaminofluorescein
diacetate for 10 min at 37°C with or without 100 nmol/l bradykinin. Different amounts of (T) and (T) (from 0 to 4.5  107/ml) platelets were then
added to the BAEC medium for 10 min at 37°C. Results are expressed as mean fluorescence intensity (MFI) and are the means  SD of experiments
performed in triplicate on six separate occasions. *p  0.001, ¶p  0.01 vs. no addition of platelets (Control).
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